The key catalyst is the Phase 3 CATT1 topline data readout in mid 2027. Cash runway appears sufficient through that event. The FDA Orphan Drug Designation for HPPD may support partnering discussions but is not a near-term value driver. Monitor enrollment completion confirmation and any early efficacy signals from the ongoing Phase 2a Hybrid CATT1 study.
Drugs in focus
VTVT drug pipeline →cadisegliatin
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 CATT1 results are positive (mid 2027), an FDA submission (NDA) would likely follow in late 2027 or 2028, with potential approval in 2028-2029, assuming no regulatory setbacks.
- Next catalyst
- None dated
What to watchThe next major catalyst is the Phase 3 CATT1 topline data readout expected around mid 2027, roughly 7 months away. Positive results would validate cadisegliatin as the first oral adjunctive therapy for T1D and could drive a significant re-rating given the stock's current valuation near its 52-week low. Negative results or delays would be severely punishing for this single-asset company. Interim updates, partnership news, or early Phase 2a Hybrid CATT1 pilot data could provide nearer-term trading catalysts.
Price Chart
Executive Summary
vTv Therapeutics reported Q3 2026 net loss of $11.6M ($0.94 per share), wider than the $8.7M loss in Q3 2025, but the per-share loss narrowed from $1.08 due to a higher share count. The company completed enrollment in its Phase 3 CATT1 trial for cadisegliatin (166 participants randomized) and expects topline results in mid 2027. Cash of $77.2M is expected to fund operations well through that readout. The FDA also granted Orphan Drug Designation to HPPD for sickle cell disease.
Key Financial Metrics
Key Facts
- Phase 3 CATT1 trial enrollment completed with 166 participants randomized; topline results expected mid 2027
- First participant randomized in Phase 2a Hybrid CATT1 pilot study for cadisegliatin in T1D patients using hybrid closed-loop insulin systems
- FDA granted Orphan Drug Designation to HPPD (HPP8668) for sickle cell disease
- Cash and cash equivalents of $77.2M as of September 30, 2026, down from $88.9M at December 31, 2025
- Q3 2026 net loss attributable to vTv shareholders was $11.6M ($0.94 per share) vs $8.7M ($1.08 per share) in Q3 2025
- RD expenses $7.5M in Q3 2026 vs $7.0M in Q3 2025, driven by Phase 3 CATT1 investment
Financial Impact
Net loss of $11.6M in Q3 2026, cash burn of ~$11.7M from $88.9M to $77.2M over nine months; no revenue in the quarter
Risk Factors
- Phase 3 CATT1 topline results are binary and not expected until mid 2027
- Cash burn rate may require additional financing before or after the readout if results are negative
- No revenue from product sales; company is entirely dependent on clinical trial outcomes and partnership income
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001641489-26-000035 |
| Document: vtvt-20261105.htm | 0001641489-26-000035 |
| Document: 0001641489-26-000035-index-headers.html | 0001641489-26-000035 |
| Document: 0001641489-26-000035-index.html | 0001641489-26-000035 |
| Document: 0001641489-26-000035.txt | 0001641489-26-000035 |
| 8-K Data (Synthetic) | 0001641489-26-000035 |
Track record
9 reports on VTVT
Filters
- Nov 16, 2026today SC 13D/A Neutral 3/10 Entry $17.69 Now $17.69 +0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $19.69 Now $17.69 −10.16% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 4/10 Viewing No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $21.03 Now $17.69 −15.88% settles Dec 7
- Oct 8, 20265w ago SC 13G/A Neutral 3/10 Entry $31.18 to $21.03 Now $17.69 −43.26% ▼ −32.55% −26.99% vs SPY
- Jun 10, 202622w ago DEFA14A Neutral 3/10 Entry $31.59 to $33.44 Now $17.69 −44.00% ▲ +5.86% +3.97% vs SPY
- May 8, 202627w ago Press Release Neutral 2/10 Entry $30.46 to $31.77 Now $17.69 −41.92% ▲ +4.30% +4.61% vs SPY
- Mar 10, 202635w ago Press Release Mixed 6/10 Entry $35.10 to $37.30 Now $17.69 −49.60% ▲ +6.27% +5.74% vs SPY
- Feb 26, 202637w ago 8-K Neutral 4/10 Entry $39.32 to $37.80 Now $17.69 −55.01% ▼ −3.87% +2.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers